Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

62 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of host factors and COVID-19 infection on the humoral immune repertoire in treated HIV.
Schnittman SR, Jung W, Fitch KV, Zanni MV, McCallum S, Lee JS, Shin S, Davis BJ, Fulda ES, Diggs MR, Giguel F, Chinchay R, Sheth AN, Fichtenbaum CJ, Malvestutto C, Aberg JA, Currier J, Lauffenburger DA, Douglas PS, Ribaudo HJ, Alter G, Grinspoon SK. Schnittman SR, et al. Among authors: malvestutto c. JCI Insight. 2023 Mar 8;8(5):e166848. doi: 10.1172/jci.insight.166848. JCI Insight. 2023. PMID: 36805331 Free PMC article.
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.
O'Brien MP, Forleo-Neto E, Musser BJ, Isa F, Chan KC, Sarkar N, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Hou P, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; Covid-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682. Epub 2021 Aug 4. N Engl J Med. 2021. PMID: 34347950 Free PMC article. Clinical Trial.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
O'Brien MP, Forleo-Neto E, Sarkar N, Isa F, Hou P, Chan KC, Musser BJ, Bar KJ, Barnabas RV, Barouch DH, Cohen MS, Hurt CB, Burwen DR, Marovich MA, Brown ER, Heirman I, Davis JD, Turner KC, Ramesh D, Mahmood A, Hooper AT, Hamilton JD, Kim Y, Purcell LA, Baum A, Kyratsous CA, Krainson J, Perez-Perez R, Mohseni R, Kowal B, DiCioccio AT, Geba GP, Stahl N, Lipsich L, Braunstein N, Herman G, Yancopoulos GD, Weinreich DM; COVID-19 Phase 3 Prevention Trial Team. O'Brien MP, et al. JAMA. 2022 Feb 1;327(5):432-441. doi: 10.1001/jama.2021.24939. JAMA. 2022. PMID: 35029629 Free PMC article. Clinical Trial.
Management of lipid disorders in patients living with HIV.
Myerson M, Malvestutto C, Aberg JA. Myerson M, et al. Among authors: malvestutto c. J Clin Pharmacol. 2015 Sep;55(9):957-74. doi: 10.1002/jcph.473. Epub 2015 Jun 23. J Clin Pharmacol. 2015. PMID: 25651539 Review.
Chronic kidney disease in HIV infection: an urban epidemic.
Wyatt CM, Winston JA, Malvestutto CD, Fishbein DA, Barash I, Cohen AJ, Klotman ME, Klotman PE. Wyatt CM, et al. AIDS. 2007 Oct 1;21(15):2101-3. doi: 10.1097/QAD.0b013e3282ef1bb4. AIDS. 2007. PMID: 17885301
In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles.
Bowman ER, Cameron C, Richardson B, Kulkarni M, Gabriel J, Kettelhut A, Hornsby L, Kwiek JJ, Turner AN, Malvestutto C, Bazan J, Koletar SL, Doblecki-Lewis S, Lederman MM, Cameron M, Klatt NR, Lake JE, Funderburg NT. Bowman ER, et al. Among authors: malvestutto c. Antimicrob Agents Chemother. 2020 Dec 16;65(1):e01755-20. doi: 10.1128/AAC.01755-20. Print 2020 Dec 16. Antimicrob Agents Chemother. 2020. PMID: 33020165 Free PMC article.
62 results